Assuming that in humans TRAF2 and TRAF3 mutations occur in premalignant cells, they may contribute to the initiation of B cell lymphomas through a similar RelB-dependent mechanism as we describe here for LMP1/CD40 mice. This evidence concerns the gene RELB and B-cell non-Hodgkin lymphoma.